Evidence map›Paper›PMID 27572108›Full record

ArticleInternational journal of oncology2016

Phosphatidylinositol glycan anchor biosynthesis, class X containing complex promotes cancer cell proliferation through suppression of EHD2 and ZIC1, putative tumor suppressors.

Makoto Nakakido, Kenji Tamura, Suyoun Chung, Koji Ueda, Risa Fujii, Kazuma Kiyotani, Yusuke Nakamura

Abstract read
In one paragraph

Article in International journal of oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Role ofBiomedical reports · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Synthesis and evaluation of NOrganic & biomolecular chemistry · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. The expression status of ZIC2 as a prognostic marker for nasopharyngeal carcinoma.International journal of clinical and experimental pathology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Makoto NakakidoSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.
Kenji TamuraSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.
Suyoun ChungSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.
Koji UedaProject for Realization of Personalized Cancer Medicine, Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Risa FujiiProject for Realization of Personalized Cancer Medicine, Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kazuma KiyotaniSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.
Yusuke NakamuraSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We identified phosphatidylinositol glycan anchor biosynthesis, class X (PIGX), which plays a critical role in the biosynthetic pathway of glycosylphosphatidylinositol (GPI)-anchor motif, to be upregulated highly and frequently in breast cancer cells. Knockdown of PIGX as well as reticulocalbin 1 (RCN1) and reticulocalbin 2 (RCN2), which we found to interact with PIGX and was indicated to regulate calcium-dependent activities, significantly suppressed the growth of breast cancer cells. We also identified PIGX to be a core protein in an RCN1/PIGX/RCN2 complex. Microarray analysis revealed that the expression of two putative tumor suppressor genes, Zic family member 1 (ZIC1) and EH-domain containing 2 (EHD2), were upregulated commonly in cells in which PIGX, RCN1, or RCN2 was knocked down, suggesting that this RCN1/PIGX/RCN2 complex could negatively regulate the expression of these two genes and thereby contribute to human breast carcinogenesis. Our results imply that PIGX may be a good candidate molecule for development of novel anticancer drugs for breast cancer.

Indexed as

Breast NeoplasmsCalcium-Binding ProteinsCarrier ProteinsCell Line, TumorCell ProliferationDown-RegulationFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHeLa CellsHumansMannosyltransferasesMCF-7 CellsTranscription FactorsUp-RegulationCalcium-Binding ProteinsCarrier ProteinsEHD2 protein, humanMannosyltransferasesPIGX protein, humanRCN1 protein, humanRCN2 protein, humanTranscription FactorsZIC1 protein, human

Identifiers

PMID27572108
PMCPMC4948962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.